TrialInvestigational new drugs2012

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.

György Bodoky et al.PubMed ↗Publisher ↗

No numbers read from the abstract.